JP2017510257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510257A5 JP2017510257A5 JP2016554603A JP2016554603A JP2017510257A5 JP 2017510257 A5 JP2017510257 A5 JP 2017510257A5 JP 2016554603 A JP2016554603 A JP 2016554603A JP 2016554603 A JP2016554603 A JP 2016554603A JP 2017510257 A5 JP2017510257 A5 JP 2017510257A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- seq
- car
- cell lymphoma
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 23
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 14
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 claims description 11
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 claims description 11
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 10
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 10
- 208000000389 T-cell leukemia Diseases 0.000 claims description 8
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 230000003211 malignant effect Effects 0.000 claims description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 claims description 4
- 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 claims description 4
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 claims description 2
- 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 claims description 2
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 208000028774 intestinal disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000005962 mycosis fungoides Diseases 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403905A GB201403905D0 (en) | 2014-03-05 | 2014-03-05 | Method |
| GB1403905.1 | 2014-03-05 | ||
| GB1416908.0 | 2014-09-25 | ||
| GB201416908A GB201416908D0 (en) | 2014-09-25 | 2014-09-25 | Method |
| PCT/GB2015/050643 WO2015132598A1 (en) | 2014-03-05 | 2015-03-05 | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107689A Division JP6767931B2 (ja) | 2014-03-05 | 2017-05-31 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2020054667A Division JP7149304B2 (ja) | 2014-03-05 | 2020-03-25 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510257A JP2017510257A (ja) | 2017-04-13 |
| JP2017510257A5 true JP2017510257A5 (enExample) | 2018-02-22 |
| JP6767872B2 JP6767872B2 (ja) | 2020-10-14 |
Family
ID=52649058
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554603A Active JP6767872B2 (ja) | 2014-03-05 | 2015-03-05 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2017107689A Active JP6767931B2 (ja) | 2014-03-05 | 2017-05-31 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2020054667A Active JP7149304B2 (ja) | 2014-03-05 | 2020-03-25 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2021150189A Withdrawn JP2021184773A (ja) | 2014-03-05 | 2021-09-15 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2024060080A Pending JP2024074907A (ja) | 2014-03-05 | 2024-04-03 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107689A Active JP6767931B2 (ja) | 2014-03-05 | 2017-05-31 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2020054667A Active JP7149304B2 (ja) | 2014-03-05 | 2020-03-25 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2021150189A Withdrawn JP2021184773A (ja) | 2014-03-05 | 2021-09-15 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2024060080A Pending JP2024074907A (ja) | 2014-03-05 | 2024-04-03 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20170066827A1 (enExample) |
| EP (3) | EP3125934B1 (enExample) |
| JP (5) | JP6767872B2 (enExample) |
| KR (3) | KR102235202B1 (enExample) |
| CN (4) | CN112094347A (enExample) |
| AU (3) | AU2015225944B2 (enExample) |
| BR (1) | BR112016020304B1 (enExample) |
| CA (1) | CA2940564C (enExample) |
| CL (4) | CL2016002195A1 (enExample) |
| CU (1) | CU24475B1 (enExample) |
| DK (2) | DK3125934T3 (enExample) |
| ES (2) | ES2758173T3 (enExample) |
| FI (1) | FI3241561T3 (enExample) |
| HU (2) | HUE071755T2 (enExample) |
| IL (3) | IL278878B (enExample) |
| MX (3) | MX2016010856A (enExample) |
| MY (1) | MY173567A (enExample) |
| PE (2) | PE20170125A1 (enExample) |
| PH (3) | PH12016501646B1 (enExample) |
| PL (2) | PL3241561T3 (enExample) |
| PT (2) | PT3125934T (enExample) |
| RU (2) | RU2021101502A (enExample) |
| SG (3) | SG11201606583VA (enExample) |
| WO (1) | WO2015132598A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230027993A1 (en) | 2014-03-05 | 2023-01-26 | Autolus Limited | Methods |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| US12116633B2 (en) | 2014-10-03 | 2024-10-15 | Oxford University Innovation Limited | Analysis of T-cell monotypia |
| CA2937157A1 (en) * | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
| AU2017366739B2 (en) | 2016-12-02 | 2023-11-23 | Angeles Therapeutics, Inc. | Synthetic immune receptors and methods of use thereof |
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3235295C (en) | 2017-02-20 | 2024-11-19 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| PE20200006A1 (es) | 2017-04-04 | 2020-01-06 | Hoffmann La Roche | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap |
| GB201709203D0 (en) * | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| RU2020111554A (ru) * | 2017-08-23 | 2021-09-23 | Драгонфлай Терапьютикс, Инк. | Белки, связывающие nkg2d, cd16 и опухолеассоциированный антиген |
| WO2019129850A1 (en) * | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| EP3684399A1 (en) * | 2017-12-29 | 2020-07-29 | Cellectis | Method for improving production of car t cells |
| GB201800298D0 (en) * | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
| WO2019139987A1 (en) | 2018-01-09 | 2019-07-18 | Elstar Therapeutics, Inc. | Calreticulin binding constructs and engineered t cells for the treatment of diseases |
| WO2019143961A2 (en) * | 2018-01-19 | 2019-07-25 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| US12215157B2 (en) | 2018-02-20 | 2025-02-04 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| US20210283180A1 (en) * | 2018-07-06 | 2021-09-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Car t cell therapy to target t cell specific cancers |
| US20210277120A1 (en) * | 2018-07-18 | 2021-09-09 | The General Hospital Corporation | Compositions and methods for treatment of t cell malignancies |
| GB201812650D0 (en) | 2018-08-03 | 2018-09-19 | Autolus Ltd | Molecular assessment of TRBC usage |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| GB201817172D0 (en) | 2018-10-22 | 2018-12-05 | Autolus Ltd | Antibody |
| GB201817822D0 (en) * | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| JP2022523502A (ja) * | 2019-01-29 | 2022-04-25 | シャンハイ ジャオ トン ユニバーシティ | キメラ抗原受容体およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| GB2599228B (en) * | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN114127112A (zh) * | 2019-02-21 | 2022-03-01 | 马伦戈治疗公司 | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 |
| CN110317266A (zh) * | 2019-07-17 | 2019-10-11 | 东北农业大学 | 三种scFv抗体、其编码基因及其在制备治疗或预防O型口蹄疫病制剂中的应用 |
| JP2023509708A (ja) | 2020-01-03 | 2023-03-09 | マレンゴ・セラピューティクス，インコーポレーテッド | 抗ｔｃｒ抗体分子およびその使用 |
| WO2021188454A1 (en) * | 2020-03-16 | 2021-09-23 | Marengo Therapeutics, Inc. | Engineered cell compositions and methods of use thereof |
| GB202004263D0 (en) * | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| US20230133554A1 (en) | 2020-04-09 | 2023-05-04 | Autolus Limited | Molecule |
| KR20230028242A (ko) * | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도 |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| CN111537735A (zh) * | 2020-05-15 | 2020-08-14 | 江西赛基生物技术有限公司 | 抗体检测试剂盒以及在免疫分析方面的应用 |
| CN111549044B (zh) * | 2020-07-13 | 2020-10-23 | 北京市肿瘤防治研究所 | 靶向trbc1 car-t细胞的制备方法与应用 |
| EP4200401B1 (en) * | 2020-08-18 | 2024-07-24 | Medigene Immunotherapies GmbH | Enrichment of t cells using an anti-cbeta antibody |
| KR20230074487A (ko) * | 2020-08-26 | 2023-05-30 | 마렝고 테라퓨틱스, 인크. | Trbc1 또는 trbc2를 검출하는 방법 |
| CA3211203A1 (en) * | 2021-02-17 | 2022-08-25 | The Johns Hopkins University | Methods and materials for treating clonal t cell expansions |
| WO2022177870A1 (en) * | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| GB202112923D0 (en) * | 2021-09-10 | 2021-10-27 | Ucl Business Ltd | Binding domain |
| CN120076829A (zh) | 2022-10-18 | 2025-05-30 | 明治制果药业株式会社 | T细胞肿瘤的治疗剂 |
| WO2024236163A1 (en) | 2023-05-17 | 2024-11-21 | Morphosys Ag | T cell receptor beta constant region 2 (trbc2) antibodies |
| WO2024256823A1 (en) | 2023-06-14 | 2024-12-19 | Autolus Limited | Treatment of trbc1-positive t cell malignancies |
| WO2025007013A2 (en) * | 2023-06-28 | 2025-01-02 | The Johns Hopkins University | Trbc targeting antibody-drug conjugates |
| GB202310981D0 (en) | 2023-07-18 | 2023-08-30 | Autolus Ltd | Method |
| WO2025051339A1 (en) * | 2023-09-05 | 2025-03-13 | Tiber Biotech Srl | SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR |
| WO2025096673A1 (en) * | 2023-10-30 | 2025-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising cells targeting cancer and methods of using the same |
| WO2025202622A1 (en) * | 2024-03-26 | 2025-10-02 | Oxford University Innovation Limited | Antibodies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930701620A (ko) * | 1990-08-09 | 1993-06-12 | 프레드릭 에이. 란길레 | 재조합 dna 백터를 이용하여 인체 t-세포 리셉터 성분에 대한 단일 클론성 항체의 제조방법 |
| US6790604B1 (en) * | 1998-05-12 | 2004-09-14 | Stefan A. Cohen | Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells |
| WO2003093318A1 (en) * | 2002-04-29 | 2003-11-13 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
| RU2355703C2 (ru) * | 2002-10-09 | 2009-05-20 | Медиджен Лимитед | Одноцепочечные рекомбинантные т-клеточные рецепторы |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US7741045B2 (en) * | 2006-11-16 | 2010-06-22 | General Electric Company | Sequential analysis of biological samples |
| WO2009151628A2 (en) * | 2008-06-12 | 2009-12-17 | Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services | Monitoring tcr-b to determine hiv therapy and disease progression |
| WO2010027797A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
| SI2519543T1 (sl) * | 2009-12-29 | 2016-08-31 | Emergent Product Development Seattle, Llc | Beljakovine, ki se vežejo s heterodimeri in njihova uporaba |
| JP6000507B2 (ja) * | 2010-09-30 | 2016-09-28 | パナソニックヘルスケアホールディングス株式会社 | 診療情報登録装置 |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
| DK3473707T3 (da) * | 2012-05-25 | 2025-03-17 | Cellectis | Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi |
| US10443100B2 (en) * | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| RU2017113134A (ru) * | 2014-09-19 | 2018-10-19 | Регенерон Фармасьютикалз, Инк. | Химерные антигенные рецепторы |
| BR112017020750A2 (pt) * | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
-
2015
- 2015-03-05 EP EP15709319.6A patent/EP3125934B1/en active Active
- 2015-03-05 FI FIEP17172755.5T patent/FI3241561T3/fi active
- 2015-03-05 CN CN202010858243.4A patent/CN112094347A/zh active Pending
- 2015-03-05 EP EP17172755.5A patent/EP3241561B1/en active Active
- 2015-03-05 ES ES15709319T patent/ES2758173T3/es active Active
- 2015-03-05 PL PL17172755.5T patent/PL3241561T3/pl unknown
- 2015-03-05 PE PE2016001548A patent/PE20170125A1/es unknown
- 2015-03-05 WO PCT/GB2015/050643 patent/WO2015132598A1/en not_active Ceased
- 2015-03-05 DK DK15709319.6T patent/DK3125934T3/da active
- 2015-03-05 SG SG11201606583VA patent/SG11201606583VA/en unknown
- 2015-03-05 ES ES17172755T patent/ES3033286T3/es active Active
- 2015-03-05 CN CN201580011306.XA patent/CN106068276B/zh active Active
- 2015-03-05 PT PT157093196T patent/PT3125934T/pt unknown
- 2015-03-05 EP EP25172928.1A patent/EP4610654A2/en active Pending
- 2015-03-05 CN CN202010859460.5A patent/CN112094353A/zh active Pending
- 2015-03-05 MY MYPI2016703188A patent/MY173567A/en unknown
- 2015-03-05 DK DK17172755.5T patent/DK3241561T3/da active
- 2015-03-05 SG SG10201906460PA patent/SG10201906460PA/en unknown
- 2015-03-05 KR KR1020207006445A patent/KR102235202B1/ko active Active
- 2015-03-05 MX MX2016010856A patent/MX2016010856A/es active IP Right Grant
- 2015-03-05 KR KR1020167027423A patent/KR102088082B1/ko active Active
- 2015-03-05 CN CN202410891896.0A patent/CN118852462A/zh active Pending
- 2015-03-05 KR KR1020207006444A patent/KR102235201B1/ko active Active
- 2015-03-05 PH PH1/2016/501646A patent/PH12016501646B1/en unknown
- 2015-03-05 PE PE2021000759A patent/PE20211887A1/es unknown
- 2015-03-05 IL IL278878A patent/IL278878B/en unknown
- 2015-03-05 JP JP2016554603A patent/JP6767872B2/ja active Active
- 2015-03-05 BR BR112016020304-6A patent/BR112016020304B1/pt active IP Right Grant
- 2015-03-05 CU CU2016000129A patent/CU24475B1/es unknown
- 2015-03-05 RU RU2021101502A patent/RU2021101502A/ru unknown
- 2015-03-05 HU HUE17172755A patent/HUE071755T2/hu unknown
- 2015-03-05 SG SG10201906461SA patent/SG10201906461SA/en unknown
- 2015-03-05 CA CA2940564A patent/CA2940564C/en active Active
- 2015-03-05 AU AU2015225944A patent/AU2015225944B2/en active Active
- 2015-03-05 RU RU2016138421A patent/RU2744046C2/ru active
- 2015-03-05 PT PT171727555T patent/PT3241561T/pt unknown
- 2015-03-05 HU HUE15709319A patent/HUE047641T2/hu unknown
- 2015-03-05 PL PL15709319T patent/PL3125934T3/pl unknown
- 2015-03-05 US US15/123,287 patent/US20170066827A1/en not_active Abandoned
- 2015-03-05 PH PH1/2020/550202A patent/PH12020550202B1/en unknown
-
2016
- 2016-08-04 IL IL247110A patent/IL247110A0/en active IP Right Grant
- 2016-08-19 MX MX2019013845A patent/MX2019013845A/es unknown
- 2016-08-19 MX MX2019013846A patent/MX2019013846A/es unknown
- 2016-09-01 CL CL2016002195A patent/CL2016002195A1/es unknown
-
2017
- 2017-05-26 US US15/606,480 patent/US20170334998A1/en not_active Abandoned
- 2017-05-31 JP JP2017107689A patent/JP6767931B2/ja active Active
-
2018
- 2018-10-30 CL CL2018003096A patent/CL2018003096A1/es unknown
-
2019
- 2019-06-07 CL CL2019001567A patent/CL2019001567A1/es unknown
- 2019-06-07 CL CL2019001568A patent/CL2019001568A1/es unknown
- 2019-07-09 AU AU2019204925A patent/AU2019204925B2/en active Active
- 2019-07-09 AU AU2019204921A patent/AU2019204921C1/en active Active
-
2020
- 2020-03-25 JP JP2020054667A patent/JP7149304B2/ja active Active
- 2020-04-01 PH PH12020550203A patent/PH12020550203A1/en unknown
- 2020-11-22 IL IL278879A patent/IL278879B2/en unknown
-
2021
- 2021-09-15 JP JP2021150189A patent/JP2021184773A/ja not_active Withdrawn
-
2024
- 2024-04-03 JP JP2024060080A patent/JP2024074907A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510257A5 (enExample) | ||
| RU2016138421A (ru) | ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА | |
| Vogrig et al. | Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors | |
| Oweida et al. | Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration | |
| Kamiya et al. | Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells | |
| Unterrainer et al. | PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions | |
| Zhou et al. | Chimeric antigen receptor T cells targeting HERV-K inhibit breast cancer and its metastasis through downregulation of Ras | |
| AU2025205213A1 (en) | Chimeric antigen receptor T cells targeting the tumor microenvironment | |
| JP2020529830A5 (enExample) | ||
| JP2020511936A5 (enExample) | ||
| Li et al. | CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice | |
| US20190391152A1 (en) | Markers selectively deregulated in tumor-infiltrating regulatory t cells | |
| JP2020503891A5 (enExample) | ||
| JP2019519208A5 (enExample) | ||
| JP2016196468A5 (enExample) | ||
| JP2020527027A5 (enExample) | ||
| JP2019531056A5 (enExample) | ||
| JP2018518939A5 (enExample) | ||
| JP2018536436A5 (enExample) | ||
| JP2018531014A5 (enExample) | ||
| JP2019507762A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2018500014A5 (enExample) | ||
| NZ773507A (en) | Chimeric antigen receptor | |
| JP2017501129A5 (enExample) |